Review
Urology & Nephrology
Mathieu Roumiguie, Ashish M. Kamat, Trinity J. Bivalacqua, Seth P. Lerner, Wassim Kassouf, Andreas Bohle, Maurizio Brausi, Roger Buckley, Raj Persad, Marc Colombel, Donald Lamm, Juan Palou-Redorta, Mark Soloway, Ken Brothers, Gary Steinberg, Yair Lotan, Richard Sylvester, J. Alfred Witjes, Peter C. Black
Summary: The study aims to develop optimal trial design for patients with BCG-exposed NMIBC, emphasizing the need to define the disease state clearly and providing specific recommendations and guidance.
Article
Urology & Nephrology
Francesco Soria, David D'Andrea, Mohammad Abufaraj, Marco Moschini, Andrea Giordano, Kilian M. Gust, Pierre I. Karakiewicz, Marek Babjuk, Paolo Gontero, Shahrokh F. Shariat
Summary: This study aimed to assess risk stratification for intermediate-risk NMIBC patients in order to provide a practical tool for selecting optimal adjuvant therapy. The findings showed that age, early recurrence, and tumor size were independent predictors of progression, and the generated nomogram outperformed standard strategies in predicting disease progression.
EUROPEAN UROLOGY FOCUS
(2021)
Article
Oncology
Ildiko Kocsmar, Eva Kocsmar, Gabor Pajor, Janina Kulka, Eszter Szekely, Glen Kristiansen, Oliver Schilling, Peter Nyirady, Andras Kiss, Zsuzsa Schaff, Peter Riesz, Gabor Lotz
Summary: The addition of chromosome 17 polysomy/HER2 amplification status improves the accuracy of risk assessment for non-muscle-invasive bladder cancer (NMIBC) and provides a simple solution in uro-oncology practice.
Article
Oncology
Patrick J. Hensley, Valeria Panebianco, Eugene Pietzak, Alexander Kutikov, Raghu Vikram, Matthew D. Galsky, Shahrokh F. Shariat, Morgan Roupret, Ashish M. Kamat
Summary: Staging of bladder cancer is crucial for prognosis and treatment decisions, but traditional methods have limitations. Novel biomarkers and imaging modalities, particularly MRI, show promising potential to improve diagnostic accuracy in bladder cancer staging.
EUROPEAN UROLOGY ONCOLOGY
(2022)
Article
Pathology
Michelle R. Downes, Katherine Lajkosz, Cynthia Kuk, Bruce Gao, Girish S. Kulkarni, Theodorus H. van der Kwast
Summary: This study found that combining the World Health Organization (WHO) 1973 and 2004 grading systems into a hybrid three-tier or four-tier system can better stratify patients with non-muscle invasive bladder cancer (NMIBC). This new grading system showed better predictive ability for patients' progression and event-free survival.
Article
Health Care Sciences & Services
Hendrik Juette, Moritz Reike, Ralph M. Wirtz, Maximilian Kriegmair, Philipp Erben, Karl Tully, Veronika Weyerer, Markus Eckstein, Arndt Hartmann, Sebastian Eidt, Felix Wezel, Christian Bolenz, Andrea Tannapfel, Joachim Noldus, Florian Roghmann
Summary: Patients with muscle-invasive bladder cancer (MIBC) who undergo neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC), especially those with higher expression levels of ERBB2, ESR1, or KRT20, have a significantly higher chance of achieving pathological complete response (pCR) after treatment. These findings suggest potential improvements in patient selection for NAC in MIBC.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Urology & Nephrology
Wei Shen Tan, Roberto Contieri, Nicolo Maria Buffi, Giovanni Lughezzani, Valentina Grajales, Mark Soloway, Paolo Casale, Rodolfo Hurle, Ashish M. Kamat
Summary: The purpose of this study was to determine whether the International Bladder Cancer Group IR-NMIBC scoring system can predict the need for delayed transurethral resection of bladder tumor in low-grade nonmuscle-invasive bladder cancer patients managed by active surveillance. The study found that the scoring system can predict the risk of subsequent transurethral resection of bladder tumor in patients on active surveillance.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Hiroshi Fukushima, Shingo Moriyama, Yuma Waseda, Shohei Fukuda, Sho Uehara, Hajime Tanaka, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Kazutaka Saito, Yasuhisa Fujii
Summary: This study investigated the role of bladder neck involvement (BNI) in risk substratification of intermediate-risk NMIBC patients and found that BNI can effectively sub-stratify patients based on their risks of progression and recurrence, assisting in determining follow-up and therapeutic strategies for these patients.
EUROPEAN UROLOGY FOCUS
(2021)
Review
Urology & Nephrology
Ibrahim Jubber, Sean Ong, Laura Bukavina, Peter C. Black, Eva Comperat, Ashish M. Kamat, Lambertus Kiemeney, Nathan Lawrentschuk, Seth P. Lerner, Joshua J. Meeks, Holger Moch, Andrea Necchi, Valeria Panebianco, Srikala S. Sridhar, Ariana Znaor, James W. F. Catto, Marcus G. Cumberbatch
Summary: Bladder cancer is a common disease worldwide, and external risk factors and the wider exposome contribute significantly to its development. Establishing a clear understanding of these risk factors is key to prevention.
Review
Oncology
Francesca Sanguedolce, Beppe Calo, Vito Mancini, Magda Zanelli, Andrea Palicelli, Maurizio Zizzo, Stefano Ascani, Giuseppe Carrieri, Luigi Cormio
Summary: The biological features and prognostic/predictive role of variant histology (VH) in non-muscle invasive bladder cancer (NMIBC) were examined through a systematic literature search, revealing conflicting findings due to the rarity of these forms and heterogeneity in study populations. The presence of VH should be considered when counseling NMIBC patients for potential disease upgrade to high-risk tumors and aggressive treatment.
Article
Oncology
Elliott Diamant, Mathieu Roumiguie, Alexandre Ingels, Jerome Parra, Dimitri Vordos, Anne-Sophie Bajeot, Emmanuel Chartier-Kastler, Michel Soulie, Alexandre de la Taille, Morgan Roupret, Thomas Seisen
Summary: There is conflicting evidence regarding the use of early radical cystectomy (eRC) for high-risk non-muscle-invasive bladder cancer. This study compared the perioperative and oncological outcomes between upfront and delayed eRC. The results showed similar perioperative outcomes between the two groups, but an increased risk of upstaging after upfront eRC, which did not impact survival. Further research is needed to determine which patients might benefit from upfront eRC.
Article
Urology & Nephrology
Anke Richters, Noor van Ginkel, Richard P. Meijer, Maurits Wondergem, Ivo Schoots, Andre N. Vis, Lambertus A. L. M. Kiemeney, Bas W. G. van Rhijn, J. Alfred Witjes, Katja K. H. Aben, Laura S. Mertens
Summary: This study aims to investigate the use and staging information on lymph-node involvement provided by fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in patients with muscle-invasive bladder cancer (MIBC). The study found that MIBC patients staged with FDG-PET/CT had a higher proportion of lymph node positivity, and this technique could provide additional imaging findings that may affect subsequent treatment strategies.
Article
Immunology
Weizhuo Wang, Xi Zhang, Silin Jiang, Peng Xu, Kang Chen, Kai Li, Fei Wang, Xiang Le, Ke Zhang
Summary: This study aimed to construct a prognostic model based on differential gene expression between muscular and non-muscular invasive bladder cancer (BCa), and to investigate the prognosis of BCa patients. BCa patient data from GEO and TCGA databases were analyzed, and single-cell sequencing and microarray data were used to validate the differential gene expression. The prognostic model showed accuracy and validity, and S100A9 may be a better prognostic marker and therapeutic target for BCa.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Cell Biology
Tim Muilwijk, Murat Akand, Frank Van der Aa, Vincent De Coninck, Marc Claessens, Robert Hente, Markus Eckstein, Yves Allory, Louis Libbrecht, Steven Joniau, Thomas Gevaert
Summary: Cytokeratin 5 (CK5) is a marker of basal molecular subtypes in muscle-invasive bladder cancer (MIBC) and is associated with worse overall survival compared to luminal subtypes. However, in Ta non-muscle-invasive bladder cancer (NMIBC), CK5 expression was not confirmed as a marker of high-grade (HG) disease. Further analysis showed an inverse correlation between HG disease and CK5 expression, as well as a positive correlation between HG disease and CK20 expression. This study suggests a potential role for CK5 and CK20 in distinguishing between low-grade (LG) and HG disease in Ta NMIBC.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Urology & Nephrology
Shuo-Chieh Wu, Deukwoo Kwon, Joshua S. Jue, Felix Chen, Maria C. Velasquez Escobar, Sanoj Punnen, Dipen J. Parekh, Chad R. Ritch, Mark L. Gonzalgo
Summary: This retrospective study examined the effect of androgen suppression therapy (AST) on the recurrence and progression rate of non-muscle-invasive bladder cancer (NMIBC), finding that AST was associated with a lower risk of recurrence. Further investigation is needed to explore the potential role of AST as an adjunctive therapy for NMIBC.
EUROPEAN UROLOGY FOCUS
(2021)